Just copied and pasted a well presented positive post on ADVFN4 Jan 2023 19:28
For info....
I have monitored this company for a long time. This company was set up in 2006. The company shares have been consolidated twice due to severe dilutions, hence those former directors have been removed. Valirx has spent millions of pounds to develop VAL 201 VAL 301 and VAL 401. Yet Valirx market cap is only £7m ( at the time of writing )
VAL 201 - treatment of metastatic prostate cancer phase I/ll
Disease Impact - Overall Response Rate 54.5%
Evidence for positive disease impact has been measured using PCWG2 (Prostate Cancer Working Group 2) guidelines. These industry standard guidelines take into account both the primary tumour and metastatic tumours alongside prostate specific antigen (PSA) levels to assess whether the disease has progressed, or whether the patient has responded and halted disease progression. These guidelines provide a more comprehensive measure of disease impact than just primary tumour imaging.
Of the 12 patients dosed with VAL201, 11 patients had sufficient PCWG2-relevant data collected across multiple cycles. 6 of these 11 have been categorised as responding throughout treatment. That is, when the treatment with VAL201 was halted for a defined reason, whether or not the 6 standard cycles had been completed, these patients showed no disease progression by PCWG2 criteria with stable disease.
VAL 401 - treatment of late stage small cell lung cancer phase II/III
VAL 301 - treatment of endometriosis - pre clinical stage.
Many companies with advance clinical trials like VAL have market cap of more than £50m. The treatment of prostate/lung cancer worth billion of pounds worldwide.
The new management team is competent and will maximise shareholders and stakeholders values by minimising share dilution and collaborate with other pharma to develop VAL treatment compounds.
Good luck.
Sign In
Follow the stocks
